

AMENDMENTS TO THE CLAIMS

1. (Original) Immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a hamster or primate glycosylation.
2. (Original) Antibody according to claim 1 that contains an epitope specific for a tumor associated antigen or fragments thereof.
3. (Original) Antibody according to claim 1 that contains a mimotope triggering immune response specific for a tumor associated antigen or fragments thereof.
4. (Original) Antibody according to claim 1 or 3 that contains an Ep-CAM mimotope.
5. (Original) Antibody according to claim 1 or claim 3 that contains a Lewis-y mimotope.
6. (Currently Amended) Antibody according to ~~one of the claims 1 to 5~~claim 4, which is a chimeric or humanized antibody.
7. (Currently Amended) Antibody according to ~~one of the claims 1 to 6~~claim 4, which is an anti-idiotypic antibody.
8. (Original) Antibody according to claim 7, which is directed against the idiotype of an antibody specific for a tumor associated antigen.
9. (Currently Amended) Antibody according to ~~claims 2, 3, 7 or 8~~claim 1, wherein the antigen is selected from the group consisting of peptides or proteins, such as EpCAM, NCAM, CEA and T cell peptides, carbohydrates, such as Lewis Y, Sialyl-Tn, Globo H, and glycolipids, such as GD2, GD3 and GM2.
10. (Currently Amended) Antibody according to ~~one of the claims 1 to 9~~claim 4, which is a bi-isotopic antibody.
11. (Currently Amended) Antibody according to ~~one of the claims 1 to 10~~claim 9, wherein the antibody is an IgG1 antibody containing the IgG2a subtype amino acid sequence in the constant region.

12. (Currently Amended) Antibody according to ~~one of the claims 1 or 11~~claim 11, wherein the IgG2a subtype amino acid sequence is contained in at least one of the regions selected from the CH1, hinge, CH2 and CH3 regions.
13. (Currently Amended) Antibody according to ~~one of the claims 7 to 12~~claim 1, which is an anti-idiotypic antibody to monoclonal antibodies produced by ATCC HB 9324 or ATCC HB 9347.
14. (Currently Amended) Vaccine comprising an antibody according to ~~one of claims 1 to 13~~claim 1 in a pharmaceutical formulation.
15. (Original) Vaccine according to claim 14, wherein the pharmaceutical formulation contains an adjuvant.
16. (Original) Multicistronic antibody expression construct for producing an antibody according to claim 1 in a CHO or HEK293 expression system, which contains at least a nucleotide sequence encoding a kappa light chain and a nucleotide sequence encoding a gamma heavy chain, wherein at least one of the nucleotide sequences encoding a kappa light chain or gamma heavy chain comprises a nucleotide sequence encoding at least a part of a murine IgG2a subtype amino acid sequence, and at least two IRES elements.
17. (Original) Antibody expression construct of claim 16, wherein the nucleotide sequence encoding at least the part of the murine IgG2a subtype amino acid sequence is ligated into the nucleotide sequence encoding the kappa light chain or the gamma heavy chain by one of insertion or substitution techniques.
18. (Currently Amended) Vector comprising a promotor, an antibody-expression construct of ~~one of claims 16 or 17~~claim 16 and a transcription termination sequence.
19. (Original) Vector according to claim 18, wherein one of the IRES sequences is attenuated by an inserted sequence that downregulates the entry of the ribosomes.
20. (Currently Amended) A CHO host cell or a HEK 293 transformed with vector according to claim 18-~~or 19~~.

21. (Original) A method of producing an antibody according to claim 1 comprising
- transforming a CHO or HEK293 host cell with a multicistronic antibody-expression construct
containing at least a nucleotide sequence encoding a kappa light chain and a nucleotide sequence
encoding a gamma heavy chain, wherein at least one of the nucleotide sequences comprises a
nucleotide sequence encoding at least a part of a murine IgG2a subtype amino acid sequence, and
at least two IRES elements, and
-expressing said nucleotide sequences under the control of a single CMV promoter to produce an
intact antibody,
-transcription of a single RNA comprising protein sub-units and selection marker.
22. (Original) Method according to claim 21, wherein one of the IRES elements is an
attenuated IRES sequence, which attenuated IRES sequence downregulates the expression of a
quantitative selection marker operably linked thereto.
23. (Original) Method according to claim 22, wherein the selection marker sequence is a
gene encoding dihydrofolate reductase.
24. (Currently Amended) Method according to ~~one of claims 21 to 23~~claim 21, wherein the
nucleotide sequences are expressed by culturing transfected CHO cells that are deficient in
dihydrofolate reductase, preferably in the presence of a selective methotrexate concentration
ranging from 1 to 10 µmol/l.
25. (Currently Amended) Method according to ~~one of claims 21 to 24~~claim 21, wherein the
nucleotide sequence encoding the kappa chain and a nucleotide sequence encoding the gamma
chain are linked by an IRES sequence.
26. (Currently Amended) Method according to ~~one of claims 21 to 25~~claim 21, producing
the kappa light chain and gamma heavy chain in about equimolar quantity.
27. (Currently Amended) Method according to ~~one of claims 21 to 26~~claim 21, producing an
antibody concentration of at least 1µg/ml, preferably 5-50 µg/ml.
28. (Currently Amended) Method according to ~~one of claims 21 to 27~~claim 21, wherein the
host cell is cultured in a serum free medium.